NAALADase inhibition protects motor neurons against chronic glutamate toxicity

Ajit G. Thomas, Andrea Markl Corse, Carol F. Coccia, Masako M. Bilak, Jeffrey D Rothstein, Barbara Slusher

Research output: Contribution to journalArticle

Abstract

Glutamate toxicity is implicated in the pathogenesis of amyotrophic lateral sclerosis. The neuropeptide N-acetyl-aspartyl glutamate (NAAG) appears to function both as a storage form for glutamate and as a neuromodulator at glutamatergic synapses. N-acetylated-α-linked acidic dipeptidase (NAALADase; also termed glutamate carboxypeptidase II) yields N-acetyl aspartate (NAA) and glutamate. Prior studies have demonstrated NAALADase upregulation in motor cortex and increased NAAG, NAA and glutamate in cerebrospinal fluid from amyotrophic lateral sclerosis patients. The potent NAALADase inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA), was tested in an in vitro model of chronic glutamate-mediated motor neuron degeneration. Neuroprotection was determined (1) biochemically, by measuring choline acetyltransferase activity, (2) immunohistochemically, by counting neurofilament-H-positive motor neurons and (3) morphologically, with phase contrast microscopy. 2-PMPA (10 μM) had significant neuroprotective effects on motor neurons as evidenced by increased choline acetyltransferase activity, decreased motor neuron loss and improved gross morphology. Results suggest that NAALADase inhibitors protect against chronic glutamate-mediated motor neuron degeneration and may prove therapeutic towards amyotrophic lateral sclerosis.

Original languageEnglish (US)
Pages (from-to)177-184
Number of pages8
JournalEuropean Journal of Pharmacology
Volume471
Issue number3
DOIs
StatePublished - Jun 27 2003

Fingerprint

Glutamate Carboxypeptidase II
Motor Neurons
Glutamic Acid
Amyotrophic Lateral Sclerosis
Nerve Degeneration
Choline O-Acetyltransferase
Phase-Contrast Microscopy
Intermediate Filaments
Motor Cortex
Neuroprotective Agents
Neuropeptides
Synapses
Neurotransmitter Agents
Cerebrospinal Fluid
Up-Regulation

Keywords

  • Amyotrophic lateral sclerosis
  • GCP II
  • Glutamate
  • Motor neuron disorder
  • NAAG
  • NAALADase
  • Neuroprotection

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

NAALADase inhibition protects motor neurons against chronic glutamate toxicity. / Thomas, Ajit G.; Corse, Andrea Markl; Coccia, Carol F.; Bilak, Masako M.; Rothstein, Jeffrey D; Slusher, Barbara.

In: European Journal of Pharmacology, Vol. 471, No. 3, 27.06.2003, p. 177-184.

Research output: Contribution to journalArticle

@article{c7b577584669495094615653b2cc3e87,
title = "NAALADase inhibition protects motor neurons against chronic glutamate toxicity",
abstract = "Glutamate toxicity is implicated in the pathogenesis of amyotrophic lateral sclerosis. The neuropeptide N-acetyl-aspartyl glutamate (NAAG) appears to function both as a storage form for glutamate and as a neuromodulator at glutamatergic synapses. N-acetylated-α-linked acidic dipeptidase (NAALADase; also termed glutamate carboxypeptidase II) yields N-acetyl aspartate (NAA) and glutamate. Prior studies have demonstrated NAALADase upregulation in motor cortex and increased NAAG, NAA and glutamate in cerebrospinal fluid from amyotrophic lateral sclerosis patients. The potent NAALADase inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA), was tested in an in vitro model of chronic glutamate-mediated motor neuron degeneration. Neuroprotection was determined (1) biochemically, by measuring choline acetyltransferase activity, (2) immunohistochemically, by counting neurofilament-H-positive motor neurons and (3) morphologically, with phase contrast microscopy. 2-PMPA (10 μM) had significant neuroprotective effects on motor neurons as evidenced by increased choline acetyltransferase activity, decreased motor neuron loss and improved gross morphology. Results suggest that NAALADase inhibitors protect against chronic glutamate-mediated motor neuron degeneration and may prove therapeutic towards amyotrophic lateral sclerosis.",
keywords = "Amyotrophic lateral sclerosis, GCP II, Glutamate, Motor neuron disorder, NAAG, NAALADase, Neuroprotection",
author = "Thomas, {Ajit G.} and Corse, {Andrea Markl} and Coccia, {Carol F.} and Bilak, {Masako M.} and Rothstein, {Jeffrey D} and Barbara Slusher",
year = "2003",
month = "6",
day = "27",
doi = "10.1016/S0014-2999(03)01832-6",
language = "English (US)",
volume = "471",
pages = "177--184",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - NAALADase inhibition protects motor neurons against chronic glutamate toxicity

AU - Thomas, Ajit G.

AU - Corse, Andrea Markl

AU - Coccia, Carol F.

AU - Bilak, Masako M.

AU - Rothstein, Jeffrey D

AU - Slusher, Barbara

PY - 2003/6/27

Y1 - 2003/6/27

N2 - Glutamate toxicity is implicated in the pathogenesis of amyotrophic lateral sclerosis. The neuropeptide N-acetyl-aspartyl glutamate (NAAG) appears to function both as a storage form for glutamate and as a neuromodulator at glutamatergic synapses. N-acetylated-α-linked acidic dipeptidase (NAALADase; also termed glutamate carboxypeptidase II) yields N-acetyl aspartate (NAA) and glutamate. Prior studies have demonstrated NAALADase upregulation in motor cortex and increased NAAG, NAA and glutamate in cerebrospinal fluid from amyotrophic lateral sclerosis patients. The potent NAALADase inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA), was tested in an in vitro model of chronic glutamate-mediated motor neuron degeneration. Neuroprotection was determined (1) biochemically, by measuring choline acetyltransferase activity, (2) immunohistochemically, by counting neurofilament-H-positive motor neurons and (3) morphologically, with phase contrast microscopy. 2-PMPA (10 μM) had significant neuroprotective effects on motor neurons as evidenced by increased choline acetyltransferase activity, decreased motor neuron loss and improved gross morphology. Results suggest that NAALADase inhibitors protect against chronic glutamate-mediated motor neuron degeneration and may prove therapeutic towards amyotrophic lateral sclerosis.

AB - Glutamate toxicity is implicated in the pathogenesis of amyotrophic lateral sclerosis. The neuropeptide N-acetyl-aspartyl glutamate (NAAG) appears to function both as a storage form for glutamate and as a neuromodulator at glutamatergic synapses. N-acetylated-α-linked acidic dipeptidase (NAALADase; also termed glutamate carboxypeptidase II) yields N-acetyl aspartate (NAA) and glutamate. Prior studies have demonstrated NAALADase upregulation in motor cortex and increased NAAG, NAA and glutamate in cerebrospinal fluid from amyotrophic lateral sclerosis patients. The potent NAALADase inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA), was tested in an in vitro model of chronic glutamate-mediated motor neuron degeneration. Neuroprotection was determined (1) biochemically, by measuring choline acetyltransferase activity, (2) immunohistochemically, by counting neurofilament-H-positive motor neurons and (3) morphologically, with phase contrast microscopy. 2-PMPA (10 μM) had significant neuroprotective effects on motor neurons as evidenced by increased choline acetyltransferase activity, decreased motor neuron loss and improved gross morphology. Results suggest that NAALADase inhibitors protect against chronic glutamate-mediated motor neuron degeneration and may prove therapeutic towards amyotrophic lateral sclerosis.

KW - Amyotrophic lateral sclerosis

KW - GCP II

KW - Glutamate

KW - Motor neuron disorder

KW - NAAG

KW - NAALADase

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=0037756825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037756825&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(03)01832-6

DO - 10.1016/S0014-2999(03)01832-6

M3 - Article

C2 - 12826236

AN - SCOPUS:0037756825

VL - 471

SP - 177

EP - 184

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -